Publication

Video

Supplements and Featured Publications
BTK Inhibitors in B-Cell Lymphomas
Volume 1
Issue 1

Dr. Kahl on BTK Inhibitor Time-Definite Trials in CLL

Author(s):

Brad Kahl, MD

Brad Kahl, MD, discusses trials looking at time-definite therapy looking at BTK inhibitor combinations in chronic lymphocytic leukemia.

Brad Kahl, MD, professor in the Department of Medicine, Washington University School of Medicine in St. Louis, Siteman Cancer Center, discusses trials looking at time-definite therapy looking at BTK inhibitor combinations in chronic lymphocytic leukemia (CLL).

There are several trials combining ibrutinib (Imbruvica) with venetoclax (Venclexta) with or without a CD20-directed monoclonal antibody comparing indefinite therapy with time-definite therapy, explains Kahl. Time-definite therapy is beneficial for patients with CLL because, according to Kahl, it prevents being on therapy for many years and experiencing drug toxicity as well as financial toxicity.

Kahl is interested in seeing how these time-definite trials impact patient outcomes over time, and hopes they result in treatment options for patients with CLL.

Articles in this issue
Bruton Tyrosine Kinase Inhibitors in B-Cell Lymphomas
Bruton Tyrosine Kinase Inhibitors in B-Cell Lymphomas
Bruton Tyrosine Kinase Inhibitors in B-Cell Lymphomas
Bruton Tyrosine Kinase Inhibitors in B-Cell Lymphomas
Dr. Ghosh on Approved BTK Inhibitors in B-Cell Malignancies
Dr. Ghosh on Approved BTK Inhibitors in B-Cell Malignancies
BTK Inhibitors Revolutionize Treatment in B-Cell Malignancies, But Require AE Awareness
BTK Inhibitors Revolutionize Treatment in B-Cell Malignancies, But Require AE Awareness
Leslie Breaks Down the Growing Importance of BTK Inhibitors in B-Cell Malignancies
Leslie Breaks Down the Growing Importance of BTK Inhibitors in B-Cell Malignancies
BTK Inhibitors Boost Outcomes in B-Cell Malignancies, But Challenges Remain
BTK Inhibitors Boost Outcomes in B-Cell Malignancies, But Challenges Remain
Dr. Ma on First- and Second-Generation BTK Inhibitors in B-Cell Malignancies
Dr. Ma on First- and Second-Generation BTK Inhibitors in B-Cell Malignancies
Dr. Leslie on the Utility of BTK Inhibitors in B-Cell Malignancies
Dr. Leslie on the Utility of BTK Inhibitors in B-Cell Malignancies
Building on Current Understandings of BTK Inhibition in CLL, MCL
Building on Current Understandings of BTK Inhibition in CLL, MCL
Dr. Burke on Current FDA Indications for BTK Inhibitors in B-Cell Malignancies
Dr. Burke on Current FDA Indications for BTK Inhibitors in B-Cell Malignancies
Dr. Treon on the Evolution of BTK Inhibitors in Waldenström Macroglobulinemia
Dr. Treon on the Evolution of BTK Inhibitors in Waldenström Macroglobulinemia
Dr. Maddocks on the Role of Zanubrutinib in B-Cell Malignancies
Dr. Maddocks on the Role of Zanubrutinib in B-Cell Malignancies
BTK Inhibitors Transform Treatment in CLL, MCL, and Waldenstrom Macroglobulinemia
BTK Inhibitors Transform Treatment in CLL, MCL, and Waldenstrom Macroglobulinemia
An Expert Assessment of Available BTK Inhibitors Within the CLL Treatment Spectrum
An Expert Assessment of Available BTK Inhibitors Within the CLL Treatment Spectrum
Exploring the Role of BTK Inhibitors in B-Cell Lymphomas
Exploring the Role of BTK Inhibitors in B-Cell Lymphomas
Related Videos
Suresh S. Ramalingam, MD, FACP, FASCO, professor, Department of Hematology and Medical Oncology, Roberto C. Goizueta Distinguished Chair for Cancer Research, Emory University School of Medicine, executive director, Winship Cancer Institute of Emory University, associate vice president, cancer, Woodruff Health Sciences Center
Byoung Chol Cho, MD, PhD, professor, internal medicine, Division of Medical Oncology, Yonsei Cancer Center, Yonsei University College of Medicine
Stephen J. Freedland, MD
Ben Levy, MD, and Yan Leyfman, MD
Viktor Grünwald, MD, PhD
Aaron Gerds, MD
BDTX-1535 – A MasterKey EGFR Inhibitor Targeting Classical, Non-Classical, and the C797S Resistance Mutation To Address The Evolved Landscape Of EGFR Mutant NSCLC
Christine M. Lovly, MD, PhD, Ingram Associate Professor of Cancer Research, associate professor, medicine (hematology/oncology), Vanderbilt-Ingram Cancer Center
Daniel M. Halperin, MD, associate professor, Department of Gastrointestinal Medical Oncology, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center
Related Content
Arndt Vogel, MD
June 2nd 2024

First-Line Camrelizumab Plus Rivoceranib Maintains Survival Benefit in Unresectable HCC

Benjamin Levy, MD, clinical director, medical oncology, Johns Hopkins Sidney Kimmel Cancer Center, Sibley Memorial Hospital; associate professor, oncology, Johns Hopkins University School of Medicine
May 30th 2024

Levy Lends Insights Into the Current and Future Use of ADCs in NSCLC

Rene Adam, MD, PhD
June 2nd 2024

Liver Transplantation Plus Chemotherapy Improves 5-Year OS Rate in Patients With CRC Liver Metastases

Oncology Unplugged
May 30th 2024

Park and Sonpavde on Considerations for Enfortumab Vedotin Plus Pembrolizumab in Bladder Cancer

Taletrectinib in ROS1-positive non–small cell lung cancer: © stock.adobe.com
June 2nd 2024

Taletrectinib Yields Durable Responses in TKI Naive and Crizotinib Pretreated ROS1+ NSCLC

Don S. Dizon, MD, FACP, FASCO, of Lifespan Cancer Institute
June 2nd 2024

Nivolumab/Ipilimumab Bests Nivolumab in Ovarian and Extra-Renal Clear Cell Carcinomas